WO2016154412A9 - Combination of a pd-1 antagonist and a listeria based vaccine for treating pancreatic cancer - Google Patents

Combination of a pd-1 antagonist and a listeria based vaccine for treating pancreatic cancer Download PDF

Info

Publication number
WO2016154412A9
WO2016154412A9 PCT/US2016/023969 US2016023969W WO2016154412A9 WO 2016154412 A9 WO2016154412 A9 WO 2016154412A9 US 2016023969 W US2016023969 W US 2016023969W WO 2016154412 A9 WO2016154412 A9 WO 2016154412A9
Authority
WO
WIPO (PCT)
Prior art keywords
antagonist
combination
pancreatic cancer
based vaccine
treating pancreatic
Prior art date
Application number
PCT/US2016/023969
Other languages
French (fr)
Other versions
WO2016154412A2 (en
Inventor
Gregory L. BEATTY
Dawson KNOBLOCK
Robert Petit
Michael F. PRINCIOTTA
Anu Wallecha
Original Assignee
The Trustees Of The University Of Pennsylvania
Advaxis, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Trustees Of The University Of Pennsylvania, Advaxis, Inc. filed Critical The Trustees Of The University Of Pennsylvania
Publication of WO2016154412A2 publication Critical patent/WO2016154412A2/en
Publication of WO2016154412A9 publication Critical patent/WO2016154412A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Environmental Sciences (AREA)
  • Cell Biology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
PCT/US2016/023969 2015-03-26 2016-03-24 Combination of a pd-1 antagonist and a listeria based vaccine for treating pancreatic cancer WO2016154412A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562138644P 2015-03-26 2015-03-26
US62/138,644 2015-03-26

Publications (2)

Publication Number Publication Date
WO2016154412A2 WO2016154412A2 (en) 2016-09-29
WO2016154412A9 true WO2016154412A9 (en) 2016-11-17

Family

ID=56978635

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/023969 WO2016154412A2 (en) 2015-03-26 2016-03-24 Combination of a pd-1 antagonist and a listeria based vaccine for treating pancreatic cancer

Country Status (2)

Country Link
TW (1) TW201705968A (en)
WO (1) WO2016154412A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
CN103687611A (en) 2011-03-11 2014-03-26 阿德瓦希斯公司 Listeria-based adjuvants
KR20140134695A (en) 2012-03-12 2014-11-24 어드박시스, 인크. Suppressor cell function inhibition following listeria vaccine treatment
CN106456726A (en) 2014-02-18 2017-02-22 阿德瓦希斯公司 Biomarker directed multi-target immunotherapy
MA39849A (en) 2014-04-24 2017-03-01 Advaxis Inc Recombinant listeria vaccine strains and methods of producing the same
MA41644A (en) 2015-03-03 2018-01-09 Advaxis Inc LISTERIA-BASED COMPOSITIONS INCLUDING A MINIGEN EXPRESSION SYSTEM CODING PEPTIDES, AND METHODS OF USE THEREOF
SG11201707383PA (en) 2015-03-13 2017-10-30 Cytomx Therapeutics Inc Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
CN108368170B (en) 2015-07-13 2022-04-15 西托姆克斯治疗公司 anti-PD-1 antibodies, activatable anti-PD-1 antibodies, and methods of use thereof
RU2729116C2 (en) 2015-12-16 2020-08-04 Гритстоун Онколоджи, Инк. Identification, production and use of neoantigens
SG10202105561PA (en) 2016-11-30 2021-07-29 Advaxis Inc Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof
JP2020522486A (en) 2017-06-01 2020-07-30 サイトメックス セラピューティクス インコーポレイテッド Activatable anti-PDL1 antibody and method of using the same
JP7284156B2 (en) 2017-09-19 2023-05-30 アドバクシス， インコーポレイテッド Compositions and methods for lyophilization of bacteria or Listeria strains
AU2018348165A1 (en) 2017-10-10 2020-05-21 Gritstone Bio, Inc. Neoantigen identification using hotspots
US11885815B2 (en) 2017-11-22 2024-01-30 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens

Also Published As

Publication number Publication date
WO2016154412A2 (en) 2016-09-29
TW201705968A (en) 2017-02-16

Similar Documents

Publication Publication Date Title
WO2016154412A9 (en) Combination of a pd-1 antagonist and a listeria based vaccine for treating pancreatic cancer
HK1232153A1 (en) Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer pd-1 ido1
HK1253276A1 (en) Treatment of cancer using inhibitors of tgf-beta and pd-1
IL258955A (en) Compositions and methods for treatment of cancer
IL254131B (en) Pd-1 / pd-l1 inhibitors for the treatment of cancer
HK1252652A1 (en) Combination of a pd-1 antagonist and cpg-c type oligonucleotide for treating cancer
IL250187B (en) Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer
IL263178A (en) Pd-1 / pd-l1 inhibitors for cancer treatment
IL246760A0 (en) Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer
EP3393475A4 (en) Methods of treating cancer
EP3288383A4 (en) Methods of treating cancer
EP3169363A4 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
IL254133A0 (en) Combination of a pd-1 antagonist and eribulin for treating cancer
EP3227317A4 (en) Methods and compositons for treating cancer
EP3110443A4 (en) Combination method for treatment of cancer
EP3200815A4 (en) Methods and compositions for treating cancer
EP3353204A4 (en) Methods and compositions for treatment of cancer
EP3325006A4 (en) Methods of treating cd166-expressing cancer
EP3215140A4 (en) Compositions and methods of diazeniumdiolate-based prodrugs for treating cancer
EP3328372A4 (en) Compositions and methods of treating cancer
EP3298141A4 (en) Compositions and methods for treating cancer
EP3200801A4 (en) Methods of treating pancreatic cancer
EP3268028A4 (en) Compositions and methods for treating cancer
EP3160591A4 (en) Compositions and methods for treating cancer
AU2022231657A1 (en) Compositions and Methods for Treating Cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16769672

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16769672

Country of ref document: EP

Kind code of ref document: A2